Latest Derivatives News

Cobalt Blue Holdings is pivoting its Broken Hill Technology Centre to process battery black mass, aiming to secure a sustainable domestic feedstock for its Kwinana Cobalt Refinery and unlock near-term revenue opportunities.

Nexion Group has finalized the sale of its Nexion Networks and Blue Sky Telecom subsidiaries, pivoting its focus towards AI-driven business intelligence through Fuse Forward.

5E Advanced Materials reports progress on its California boron project with a new feasibility study and equity raises, while highlighting ongoing funding uncertainties.

Robex Resources Inc. reported a mixed Q3 2025 with higher gold revenues offset by net losses, while progressing its Kiniéro gold project and announcing a merger with Predictive Discovery Limited.

Robex Resources reported a $16.5 million net loss in Q3 2025 and completed full drawdown of its $130 million project financing facility, progressing its Kiniéro gold project with a planned first gold pour in December. The company also announced a merger agreement with Predictive Discovery Limited, signaling strategic growth.

Biotron Limited’s lead HBV drug BIT-HBV001 demonstrates superior antiviral activity and synergy with the current standard treatment Tenofovir in preclinical models, advancing hopes for a more effective Hepatitis B therapy.

Bio-Gene Technology’s natural insecticide Qcide® has earned organic listing status from the US Organic Materials Review Institute, marking a pivotal step for its entry into the organic pest control market.

Alkane Resources reports its Q1 FY2026 interim results, highlighting the integration of Mandalay Resources and key operational developments across its global mining portfolio.

Navigator Global Investments (NGI) reveals a robust business model focused on minority stakes in alternative asset managers, supported by strategic partnerships and a diversified portfolio. The company targets doubling its EBITDA by 2030 amid strong industry tailwinds.

BPH Global Ltd is pioneering a novel seaweed-based natural formulation targeting male vitality, staking a first-mover claim in this emerging segment of men’s health. The company’s R&D, led by Gaia Mariculture, aims to launch an OTC supplement with potential for clinical validation.

Pathkey.AI has teamed up with Armstrong Clinical to blend AI-driven trial predictions with expert clinical strategy, aiming to boost early-phase trial success and accelerate drug development in Australia and beyond.

NeuroScientific Biopharmaceuticals has initiated treatment of its fourth patient under the Special Access Scheme for StemSmart™, progressing towards a Phase 2 trial targeting severe Crohn’s disease.